Spotlight: January-April 2023
Words by Jade Williams

GOLD looks back at some of the top news stories from the pharmaceutical industry over the last few months, covering landmark therapy approvals, insulin price cuts and much more
26 January
NICE approves Kite’s ground-breaking CAR-T therapy to treat blood cancer
01 February
AbbVie’s Crohn’s disease drug Rinvoq wins MHRA approval
08 February
NICE recommends Novo Nordisk’s Wegovy weight loss drug to NHS
17 February
Christi Shaw announces her departure as Kite’s CEO
01 March
Eli Lilly announces 70% price cut to most-prescribed insulins
02 March
UK increases statutory scheme payment percentage to 27.5% for 2023
05 March
Moderna selects Oxford, UK as location for new innovation and technology centre
10 March
Silicon Valley Bank crashes and sends shock waves through digital health industry
13 March
Pfizer acquires Seagen in $43bn deal to boost oncology portfolio
14 March
Novo Nordisk to cut insulin prices by up to 75% in early 2024
16 March
Sanofi slashes cost of most-prescribed insulin by 78%
21 March
MHRA announces biggest overhaul of clinical trial approval processes for 20 years
This feature appears in GOLD 27 – read the full issue here.